Iñaki Bueno, formulation and manufacturing manager at Idifarma tells us more about the ins and outs, challenges, advantages and latest developments in coatings and capsules.
The introduction of new technologies over the last decade has paved the way for pharmaceutical packaging companies to explore new and innovative solutions, improve their operations and drive efficiencies across the supply chain. Here, Dexter Tjoa, di
An increase in clopidogrel prescriptions could be seen in the US and Europe for secondary ischaemic stroke prevention as a result of the outcomes of the Phase III POINT trial, according to data and analytics company, GlobalData.
Five years on from the adoption of the EU falsified medicines directive (2011/62/EU) and the challenge continues. Here, Vincenzo Salvatore, BonelliErede (Milan), looks at the reasoning behind the directive and potential next steps
After a preview of TraceLink’s second annual Global Drug Supply, Safety and Traceability survey has revealed disparity in terms of readiness for the FMD between pharma companies and CMOs, three experts give us their perspectives on serialisation
As the falsified medicines directive is set to come into full force early next year, Christian Taylor, serialisation business consultant, Zetes, looks at the key challenges and practical questions relating to achieving compliance in more detail.
In this article, Marco Baietti, commercial director at SEA Vision, weighs up the advantages of implementing aggregation, what the future holds and the current levels of adoption within the industry.
In this guide, Manuel Duval, PhD, from Scientist.com looks at how pharma and biopharma companies can best prepare for the impact of big data in healthcare.
Here, Scott Allison, president, Life Sciences & Healthcare, DHL, and Keith Turner, CIO Chief Development Office, Life Sciences & Healthcare, Service Logistics, DHL Supply Chain, look at the importance of blockchain in logistics.
Here, Dr Chitra Lele, chief scientific officer at Sciformix Corporation discusses the real-world evidence's (RWE’s) continuum and how it could bridge the gap between clinical development and patient access.
Contract research organisation (CRO), Reaction Biology, has partnered with an open science drug discovery and development company, M4K Pharma, in the fight against diffuse intrinsic pontine glioma (DIPG) — a rare paediatric brain cancer.
Pooja Phogat, regulation and compliance expert at Kinapse, advises on the best approaches to balancing the risk of patient re-identification with the need for greater data utility.
